JP2015531371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015531371A5 JP2015531371A5 JP2015534463A JP2015534463A JP2015531371A5 JP 2015531371 A5 JP2015531371 A5 JP 2015531371A5 JP 2015534463 A JP2015534463 A JP 2015534463A JP 2015534463 A JP2015534463 A JP 2015534463A JP 2015531371 A5 JP2015531371 A5 JP 2015531371A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- heteroaryl
- aryl
- cycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- -1 CF 3 Inorganic materials 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
- 208000013593 acute megakaryoblastic leukemia Diseases 0.000 claims 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000004221 bone function Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707661P | 2012-09-28 | 2012-09-28 | |
| US61/707,661 | 2012-09-28 | ||
| PCT/US2013/032588 WO2014051698A1 (en) | 2012-09-28 | 2013-03-15 | Fused heterocyclic compounds as selective bmp inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015531371A JP2015531371A (ja) | 2015-11-02 |
| JP2015531371A5 true JP2015531371A5 (enExample) | 2016-05-12 |
| JP6430383B2 JP6430383B2 (ja) | 2018-11-28 |
Family
ID=50388847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015534463A Expired - Fee Related JP6430383B2 (ja) | 2012-09-28 | 2013-03-15 | 選択的ｂｍｐ阻害剤としての縮合複素環化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9738636B2 (enExample) |
| EP (1) | EP2900238B1 (enExample) |
| JP (1) | JP6430383B2 (enExample) |
| KR (1) | KR102092988B1 (enExample) |
| CN (1) | CN104768548B (enExample) |
| AU (1) | AU2013324396B2 (enExample) |
| BR (1) | BR112015007136A2 (enExample) |
| CA (1) | CA2886187C (enExample) |
| DK (1) | DK2900238T3 (enExample) |
| ES (1) | ES2660051T3 (enExample) |
| SG (1) | SG11201503299YA (enExample) |
| WO (1) | WO2014051698A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013004685B1 (pt) | 2010-09-01 | 2021-09-21 | Thomas Jefferson University | Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular |
| TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為ｌｓｄ１抑制劑之環丙胺 |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| MY191796A (en) | 2015-04-03 | 2022-07-15 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| US10501438B2 (en) | 2015-08-11 | 2019-12-10 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| CN114605387A (zh) | 2015-08-12 | 2022-06-10 | 埃皮吉纳提克斯股份有限公司 | 取代的苯并咪唑、它们的制备和它们作为药物的用途 |
| US10501459B2 (en) | 2015-10-21 | 2019-12-10 | Neomed Institute | Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors |
| US10519151B2 (en) * | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| EP3468554B1 (en) | 2016-06-08 | 2023-08-09 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
| HUE057328T2 (hu) * | 2016-07-20 | 2022-05-28 | Novartis Ag | Aminopiridin származékok és szelektív ALK-2 gátlóként való alkalmazásuk |
| WO2018053126A1 (en) | 2016-09-14 | 2018-03-22 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| US20200054643A1 (en) * | 2017-01-18 | 2020-02-20 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| US10745400B2 (en) | 2018-03-14 | 2020-08-18 | Vanderbuilt University | Inhibition of BMP signaling, compounds, compositions and uses thereof |
| CN110496127A (zh) * | 2018-05-17 | 2019-11-26 | 中国科学院上海生命科学研究院 | 一种热休克因子1的抑制剂、其制备方法和应用 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CR20210336A (es) * | 2018-12-20 | 2021-12-06 | Incyte Corp | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CR20220280A (es) | 2019-11-22 | 2022-09-02 | Incyte Corp | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 |
| IL297437A (en) | 2020-05-13 | 2022-12-01 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| WO2021257532A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
| WO2024205336A1 (ko) * | 2023-03-30 | 2024-10-03 | 에이치엘비생명과학알앤디 주식회사 | 튜블린 저해 활성을 갖는 약학적 조성물 |
| WO2024239187A1 (zh) * | 2023-05-22 | 2024-11-28 | 睿健医药科技(苏州)有限公司 | Bmpr1b抑制剂在诱导发育中的应用、诱导培养基 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2562071B1 (fr) * | 1984-03-30 | 1986-12-19 | Sanofi Sa | Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB9927687D0 (en) * | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
| JP4747396B2 (ja) | 2000-05-17 | 2011-08-17 | 日立化成工業株式会社 | 接着剤組成物、それを用いた回路端子の接続方法及び回路端子の接続構造 |
| DE60230160D1 (de) | 2001-02-20 | 2009-01-15 | Astrazeneca Ab | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
| US7125888B2 (en) | 2002-05-02 | 2006-10-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| DOP2006000051A (es) * | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| ES2377821T3 (es) | 2006-10-11 | 2012-04-02 | Amgen Inc. | Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos. |
| US8895745B2 (en) | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
| CA2672213C (en) * | 2006-12-22 | 2016-02-16 | Astex Therapeutics Limited | Bicyclic amine derivatives as protein tyrosine kinase inhibitors |
| ES2320955B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| EP2139888A2 (en) * | 2007-03-28 | 2010-01-06 | Array Biopharma, Inc. | Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors |
| JP5374492B2 (ja) * | 2007-04-03 | 2013-12-25 | アレイ バイオファーマ、インコーポレイテッド | 受容体チロシンキナーゼ阻害薬としてのイミダゾ［１，２−ａ］ピリジン化合物 |
| US20090005374A1 (en) | 2007-06-26 | 2009-01-01 | Melvin Jr Lawrence S | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| EA201000123A1 (ru) * | 2007-07-26 | 2010-08-30 | Новартис Аг | Органические соединения |
| PL2212323T3 (pl) * | 2007-10-17 | 2013-01-31 | Novartis Ag | Pochodne imidazo[1,2-a]pirydyny użyteczne jako inhibitory ALK |
| US8507501B2 (en) | 2008-03-13 | 2013-08-13 | The Brigham And Women's Hospital, Inc. | Inhibitors of the BMP signaling pathway |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| JPWO2009157423A1 (ja) * | 2008-06-24 | 2011-12-15 | 財団法人乙卯研究所 | 縮合環を有するオキサゾリジノン誘導体 |
| WO2010083145A1 (en) * | 2009-01-16 | 2010-07-22 | Merck Sharp & Dohme Corp. | IMIDAZO[1,2-a]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS |
| MX2011009796A (es) * | 2009-03-20 | 2011-12-14 | Amgen Inc | Inhibidores de la cinasa pi3. |
| GB0906470D0 (en) * | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| CN102971326A (zh) * | 2010-04-28 | 2013-03-13 | 百时美施贵宝公司 | 咪唑并哒嗪化合物及其在癌症中的用途 |
| AU2011246067A1 (en) | 2010-04-28 | 2012-09-27 | Daiichi Sankyo Company, Limited | [5,6] heterocyclic compound |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| US9505763B2 (en) * | 2011-07-25 | 2016-11-29 | Vanderbilt University | Cancer treatment using BMP inhibitor |
| EP2615151A1 (en) | 2011-12-23 | 2013-07-17 | Services Pétroliers Schlumberger | Compositions and methods for well cementing |
| JP2016510745A (ja) | 2013-03-04 | 2016-04-11 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | Ｂｍｐ阻害剤およびその使用方法 |
| WO2014160203A2 (en) | 2013-03-14 | 2014-10-02 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
-
2013
- 2013-03-15 CN CN201380058849.8A patent/CN104768548B/zh not_active Expired - Fee Related
- 2013-03-15 AU AU2013324396A patent/AU2013324396B2/en not_active Ceased
- 2013-03-15 ES ES13840866.1T patent/ES2660051T3/es active Active
- 2013-03-15 US US14/432,472 patent/US9738636B2/en not_active Expired - Fee Related
- 2013-03-15 SG SG11201503299YA patent/SG11201503299YA/en unknown
- 2013-03-15 KR KR1020157011027A patent/KR102092988B1/ko not_active Expired - Fee Related
- 2013-03-15 BR BR112015007136A patent/BR112015007136A2/pt not_active IP Right Cessation
- 2013-03-15 WO PCT/US2013/032588 patent/WO2014051698A1/en not_active Ceased
- 2013-03-15 DK DK13840866.1T patent/DK2900238T3/en active
- 2013-03-15 EP EP13840866.1A patent/EP2900238B1/en not_active Not-in-force
- 2013-03-15 CA CA2886187A patent/CA2886187C/en not_active Expired - Fee Related
- 2013-03-15 JP JP2015534463A patent/JP6430383B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-17 US US15/652,100 patent/US10196392B2/en active Active